Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.36 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12654530 | 0.81 | CA2 (0.44) | CA2CA9FGFR4P2RX1 | |
| SCHEMBL12654400 | 0.78 | P2RX1 (0.46) | CA2CA9FGFR4P2RX1 | |
| SCHEMBL12654516 | 0.76 | P2RX1 (0.48) | CA2CA9FGFR4P2RX1 | |
| SCHEMBL19365573 | 0.75 | CA2 (0.39) | TP53LMNATHRBCA2CA9 | |
| SCHEMBL12654101 | 0.75 | HTR2C (0.51) | CA2CA9 | |
| SCHEMBL12654527 | 0.74 | FGFR4 (0.56) | CA2CA9FGFR4 | |
| SCHEMBL12654660 | 0.74 | FGFR4 (0.46) | LMNAFGFR4 | |
| SCHEMBL12654639 | 0.74 | FGFR4 (0.49) | CA2CA9FGFR4P2RX1 | |
| SCHEMBL1820744 | 0.74 | FGFR4 (0.45) | CA2CA9FGFR4P2RX1 | |
| SCHEMBL12654515 | 0.74 | FGFR4 (0.45) | TP53LMNACA2CA9FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | TP53 349/4885LMNA 3617/4885THRB 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.